Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive–compulsive disorder: A network meta‐analysis

Abstract

AbstractObjectivesThe augmentation of serotonin reuptake inhibitors (SRIs) can be achieved by add‐on therapy with different pharmacological agents in obsessive–compulsive disorder (OCD) for a better clinical outcome. This network meta‐analysis (NMA) was conducted to evaluate and compare the effects of available augmentation agents for SRIs in OCD.MethodThe data was extracted from 59 relevant clinical trials after a literature search on MEDLINE/PubMed, Scopus, Cochrane databases and clinical trial registries. PRISMA guidelines were followed in data extraction, analysis and reporting. Random effects Bayesian NMA was done to pool the effects across the interventions for the change in Yale‐Brown Obsessive–Compulsive Scale (YBOCS) scoring from baseline to the end of the study. Network graph was built, consistency model was run, node splitting analysis was performed, treatments were ranked as per SUCRA score and meta‐regression was done for refractoriness to SRIs and duration of augmentation therapy as the predictor variables.ResultsThe drugs showing significant reduction in YBOCS scoring were pregabalin (MD:−8.1;95% CrI: −16, −0.43), memantine (MD:−6.2;95% CrI: −9.9, −2.3), lamotrigine (MD:−6;95% CrI: −12, −0.47), ondansetron (MD:−5.7;95% CrI: −11, −0.67), granisetron (MD:−5.6;95% CrI: −11, −0.44), aripiprazole (MD:−5.4;95% CrI:−9.1, −1.6), risperidone (MD:−3.3;95% CrI: −6.4, −0.20) and topiramate (MD:−5.3;95% CrI: −9.6, −0.97). The node‐split analysis showed that direct and indirect pooled effect sizes for all comparisons were comparable. Meta‐regression showed a statistically non‐significant association between YBOCS score reduction with the duration of augmentation therapy, but significant with SRI‐refractory status. Finally, the results were sorted based on certainty of evidence.ConclusionMemantine was found to be most effective augmentation agent for SRIs in OCD, followed by lamotrigine, ondansetron and granisetron with moderate certainty of evidence. The augmentation agents showed better symptom reduction in patients with SRI‐refractory OCD in comparison to non‐refractory OCD.PROSPERO registrationCRD42022360110.